Prestoma-Trial for Parastomal Hernia Prevention

Status Terminated

Clinical Trial Summary

Prestoma Trial is designed to compare the safety and efficiency of three different meshes and techniques to prevent parastomal hernia after laparoscopic or robotic-assisted abdominoperineal resection for rectal adenocarcinoma.

Clinical Trial Description

Parastomal hernia after permanent colostomy formation is a common problem. The European Hernia Society recommends the use of prophylactic mesh when the stoma is constructed. So far, there're no trials comparing the methods to prevent the parastomal hernia.

Prestoma Trial is designed to compare the most researched retromuscular mesh (Parietene Macro by Medtronic) with two different types of intraperitoneal meshes (Parietex Parastomal by Medtronic and Dynamesh IPST) in parastomal hernia prevention after laparoscopic or robotic-assisted abdominoperineal resection for rectal adenocarcinoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03527784
Study type	Interventional
Source	University of Oulu
Contact
Status	Terminated
Phase	N/A
Start date	May 3, 2018
Completion date	October 29, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05081024` - Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
Not yet recruiting	`NCT04090450` - Optimisation of Radiotherapy in Rectal Cancer (ORREC)
Recruiting	`NCT06050447` - Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Terminated	`NCT02233595` - Evaluation of Rectal Cancer Treatment Response Using PET/MRI
Completed	`NCT02935309` - Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma	Phase 1
Terminated	`NCT01887509` - Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology	N/A
Recruiting	`NCT05746195` - Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)	N/A
Active, not recruiting	`NCT03365882` - S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	Phase 2
Completed	`NCT02314182` - GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis	Phase 3
Completed	`NCT02393755` - Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT04441580` - Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in a Screening Setting	N/A
Completed	`NCT00855946` - Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy	N/A
Recruiting	`NCT06328361` - Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer	N/A
Recruiting	`NCT02107105` - Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
Terminated	`NCT03300544` - Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer	Phase 1
Active, not recruiting	`NCT03436563` - M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability	Phase 1/Phase 2
Not yet recruiting	`NCT04814784` - Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum
Recruiting	`NCT05482516` - Evaluating Novel Therapies in ctDNA Positive GI Cancers	Phase 3
Completed	`NCT02368886` - Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer	Phase 2
Active, not recruiting	`NCT02688712` - ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer	Phase 2